You may find more results for this query on our sister sites: GenomeWeb and 360Dx.
SkylineDx said that the firms will work together to develop predictive immunological signatures for BioInvent's lead therapy candidate.
Researchers have identified immune cell gene expression signatures that could one day be developed into tests to predict response to treatment.
